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Abstract
Malignant pleural mesothelioma (MPM) is an aggressive malignancy tightly associated with asbestos exposure.
The increasing incidence of MPM and its resistance to all therapeutic modalities necessitate an urgent develop-
ment of new treatments for MPM. Proteasome inhibitors (PIs) have emerged as promising agents for treating hu-
man cancers that are refractory to current chemotherapies. In this study, we characterized MG132, a commonly
used PI, for its proapoptotic and anti-invasion activities in NCI-H2452 and NCI-H2052 human thoracic MPM cell
lines to determine the therapeutic effect of PIs on MPM. We found that as low as 0.5 μM MG132 caused a sig-
nificant apoptosis in both cell lines as evidenced by DNA damage, cleavage of poly ADP-ribose polymerase and
caspases 3, 7, and 9, and mitochondrial release of Smac/DIABLO and Cytochrome c. Mitochondrial caspase ac-
tivation was found to be the underlying mechanism of the MG132-induced apoptosis. Mcl-1, among the Bcl-2 and
IAP (inhibitor of apoptosis protein) antiapoptotic family proteins tested, was proved to be a major inhibitor of the
MG132-induced apoptosis in MPM cells. Meanwhile, subapoptotic doses of MG132 inhibited the invasion of both
MPM cell lines through reducing Rac1 activity. These observations demonstrate that MG132 possesses proapop-
totic and anti-invasion activities in human MPM cells, therefore encouraging further investigations on the value of
PIs for treating MPM.
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Introduction
Malignant pleural mesothelioma (MPM) is an aggressive malignancy
that arises from the mesothelium-lined surfaces of the pleural cavities
after exposure to asbestos [1]. There are approximately 3000 new
MPM cases diagnosed each year in the United States, with an even
higher number worldwide. There are three distinct common histo-
logic subtypes of MPM based on the microscopic appearance of the
major malignant elements: epithelial, sarcomatoid, and biphasic
(mixed). Although measures have been put in place to limit further
asbestos exposure, the long latency of disease development after ex-
posure has resulted in a dramatically increasing current incidence of
MPM, with a projected peak in 2010 in the United States [2].
General resistance to currently available therapeutic modalities is
the major reason for the overall very poor clinical outcome of MPM,
which, regardless of treatment, has a median survival rate of less
than 1 year [3]. Malignant pleural mesothelioma is extremely resis-
tant to most chemotherapy regimens examined, and radiation ther-
apy is generally ineffective as a primary treatment as well [4,5].
Targeted therapies, such as antiangiogenic drugs and inhibitors of
the epidermal growth factor receptor tyrosine kinase [6], have proved
equally ineffective in prolonging MPM patient survival despite sub-
stantial overexpression of the relevant molecular targets in MPM
cells. Pemetrexed (Alimta) and cisplatin combination chemotherapy
was recently shown in a prospective randomized trial to be the best
chemotherapy regimen for MPM examined so far. However, median
survival with this therapy was still less than 1 year, and the response
rate was lower than 50% [7].
Most chemotherapeutic molecules trigger tumor cell eradication
and patient survival by inducing apoptotic cell death [7]. Caspases
play the most important role in regulating the apoptotic program.
These proteolytic enzymes are divided into initiators, such as caspases
8, 9, and 10, and effectors, such as caspases 3 and 7, depending on
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the timing of activation [8]. The mitochondrial or intrinsic caspase
activation pathway represents a fundamental mechanism in the apop-
totic response triggered by different cellular stresses [9]. Antiapototic
Bcl-2 family protein members antagonize the mitochondrial pathway
through controlling outer mitochondrial membrane permeability and
the release of mitochondrial proapoptotic factors, including Cyto-
chrome c (Cyto c) and Smac/DIABLO (Smac), into the cytosol [10].
After release into the cytosol, Cyto c stimulates formation of the apop-
tosome to activate the initiator caspase 9, whereas Smac relieves the
inhibition imposed by inhibitor of apoptosis proteins (IAPs) on cas-
pases 9, 3 and 7. The synergistic action of Cyto c and Smac leads to
full activation of caspases and cell death [9].
Mcl-1, or commonly known as the long isoform of Mcl-1 (Mcl-
1L), acts as an antiapoptotic member of the Bcl-2 family proteins and
is expressed in multiple cell lineages [11,12]. It has emerged as a key
member of this family of apoptosis control molecules. In contract to
Mcl-1L, the short isoform of Mcl-1 (Mcl-1S), like other BH3-only
proteins of the Bcl-2 family, serves as a proapoptotic protein [13].
Increased expression of Mcl-1 (or Mcl-1L) is associated with the
maintenance of cell viability and decreased expression is associated
with cell death [14].
Due to the resistance to currently available chemotherapies and
the increasing incidence of MPM, development of new treatments
for MPM is urgently needed. Proteasome inhibitors (PIs) are becom-
ing potential therapeutic agents for various types of human cancers
that are refractory to currently available therapeutic modalities. The
proteasome is a large catalytic complex that is responsible for most
nonlysosomal intracellular protein degradation. This structure is a
promising target for cancer therapy because it has been shown to
impact the cell cycle, apoptosis, proliferation, and other physiologi-
cal processes by regulating the levels of important signaling proteins
such as CDC25A, CDC25C, MDM2, p21/WAF-1, p27/KIP1, and
I-κB [15].
Limited attempts have been made to address the possibility of
using PIs in the treatment of MPM [16,17]. Although the PIs have
been claimed to induce apoptosis in MPM cells, determination of
caspase involvement and other critical molecules in regulating this
process and other anticancer activities of PIs in MPM cells warrant
further investigations. In this study, we examined anticancer activities
of MG132, a commonly used PI, in two human MPM cell lines. We
demonstrate that MG132 induces a caspase-dependent apoptotic cell
death in MPM cells and that subapoptotic doses of MG132 inhibit
MPM cell invasion possibly through inhibiting Rac1 activation, sug-
gesting that MG132 possesses antimesothelioma activities through
either activating the apoptotic pathways or targeting regulatory mol-
ecules for MPM cell invasion.
Materials and Methods
Cells, Chemicals, and Antibodies
Cell lines. NCI-H2052 and NCI-H2452, two human MPM cell
lines, and NCI-H358, a human non–small cell lung carcinoma cell
(NSCLC) line, were purchased from American Type Culture Corpo-
ration (Rockville, MD) and cultured in RPMI-1640 medium with
10% fetal bovine serum.
Chemicals. MG-132, an S26 proteasome inhibitor, Src kinase in-
hibitor I, caspase inhibitors, Z-VAD-fmk for broad spectrum cas-
pases, Z-IETD-fmk for caspase 8, Z-LEHD-fmk for caspase 9, and
Z-FA-fmk used as negative control for all caspase inhibitors, were
from EMD-CalBiochem (San Diego, CA). Caspase substrates, Ac-
DEVD-Amc for caspase 3, Ac-IETD-Amc for caspase 8, and Ac-
LEHD-Amc for caspase 9, were from BD Biosciences (San Jose,
CA). Fibronectin and proteinase inhibitor cocktail were from Sigma.
Matrigel was from Becton Dickinson Labware (Bedford, MA). Mcl-1
and XIAP siRNAs and the scrambled siRNA (control siRNA) were
from Santa Cruz Biotechnology (Santa Cruz, CA). EZ-Detect Activa-
tion Kits for Rho, Cdc42, or Rac1 were from Pierce (Rockford, IL).
Antibodies. The antibodies used in against caspases 3, 7, and 9, poly
ADP-ribose polymerase (PARP), XIAP, c-IAP1, Survivin, Cyto c, and
Smac were from Cell Signaling Technologies (Danvers, MA). Anti-
bodies against Bid, Bcl-2, β-actin, and HA tag were from Sigma. Anti-
bodies against Mcl-1 and Bcl-XLwere from Santa Cruz Biotechnology.
Cell Proliferation Assay
A total of 2 × 105 MPM cells were seeded in each T25 cul-
ture dish and were treated continuously with MG132 for a total of
96 hours. Living cells stained negative by trypan blue were counted
at 24-hour intervals.
Cell Viability Assay
A total of 1 × 104 cells growing in each well of a 96-well micro-
plate were treated withMG132 for 36 to 48 hours and then incubated
with 10 μl of WST-1 reagent (Roche, Indianapolis, IN) for 1 to
4 hours. The increase of absorbance at 420 to 480 nm relative to
the blank well control was measured for each sample using a micro-
plate spectrophotometer.
Flow Cytometry Assay
DNA fragmentation suggesting apoptotic DNA damage was indi-
cated by a distinct sub–G0/G1 peak in flow cytometry assay [18].
After treatment, approximately 1 × 105 cells were collected, fixed
in 70% ethanol, and stained with propidium iodide, and DNA con-
tent was determined on a flow cytometer (FACSCalibur; BD Bio-
sciences, San Jose, CA).
Caspase Activity Assay
A total of 40 μg of protein isolated from the cells treated with
MG132 was incubated in each reaction with 10 μg of correspond-
ing caspase substrates for 1 hour, and the activities for caspases 3,
8, and 9 were measured in a CytoFluor Multiwell Plate Reader
(PerSeptive Biosystems, Framingham, MA).
Western Blot Analysis
Conventional procedures of Western blot analysis were followed to
monitor expression and/or cleavage of apoptosis-related proteins in
MPM cells treated with MG132. RIPA buffer supplemented with
proteinase inhibitor cocktail was used to collect cell lysates.
In Vitro Cell Migration and Invasion Assays
A transwell (8-μm pore size, 24-well format; BD Biosciences)
coated with fibronectin on the bottom side of the transwell mem-
brane was used in the migration assay. The same type of transwell
coated also with Matrigel on the upper chamber was used in the in-
vasion assay. A total of 0.5 to 1 × 105 cells were loaded in each trans-
well and incubated with MG132 for 24 to 48 hours in migration and
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invasion assays. Nonmigrated cells were removed by cotton swab,
and migrated cells were fixed and stained with Diff-Quick solutions.
The transwell membrane was then mounted on a glass slide, and mi-
gratory cells of five fields under a microscope were counted for each
chamber, and the average number of migrating cells was calculated
from the total number of cells counted per chamber.
Pull-down Assay
EZ-Detect Rho Activation Kits for Rho, Cdc42, or Rac1 were
used to measure GTP-bound Rho, Cdc42, or Rac1 proteins from
MG132-treated NCI-H2452 cells. The protocol provided in the kits
was followed to precipitate GTP-bound proteins. Both GTP-bound
proteins and total proteins were subjected to Western blot analysis.
siRNA Transfection
Malignant pleural mesothelioma cells growing at approximately
60% confluence in each 60-mm culture dish were incubated with
a transfection mixture containing 60 pmol of target-specific siRNA
or scrambled siRNA and 3 μg of Lipofectamine 2000 for 5 hours
in serum-free medium. A total of 3 ml of complete medium with
10% fetal bovine serum was then added to the cells for another 24
to 48 hours of incubation. After siRNA transfection, the cells were
treated with MG132 and examined for apoptosis induction by both
cell viability assay and Western blot analysis.
Construction of Rac1-G12V Expression Vector and
Gene Transfection
cDNA of a constitutively active mutant of Rac1 (Rac1-G12V)
tagged with HA antigen in pcDNA3 vector (UMR cDNA Resource
Center, Rolla, MO) was transferred into pCEP4 vector (Invitrogen,
Carlsbad, CA). A total of 5 μg of new construct DNA with 3 μg of
Lipofectamine 2000 was mixed and applied to 1 × 106 NCI-H2052
cells. After the initial 48 hours of incubation, tumor cells were tryp-
sinized and selected by 20 μg/ml hygromycin for 25 days. The pooled
hygromycin-resistant cells were examined for expression of the Rac1-
G12V protein in Western blot analysis and then used in the invasion
assay. Vector alone–transfected cells were used as a control.
Statistics
Data from cell proliferation, cell viability, caspase activation, and
cell invasion and migration assays were expressed as the means ± SD
of at least two separate experiments. Comparison between group
means was assessed using a one-way ANOVA with the Newman-
Keuls posttest (GraphPad Prism 3.0 Software, Inc., San Diego, CA).
P < .05 was considered significant.
Results
MG132 Inhibits Growth and Induces Apoptosis of Human
MPM Cells
In our initial attempt to determine the therapeutic effect of PIs on
MPM, we chose MG132 as a prototype PI to treat both NCI-H2052
and NCI-H2452 cells. Apoptosis induction by MG132 has been re-
ported in different types of human cancer [19,20]. Our recent obser-
vations indicated that as low as 0.25 μM MG132 can induce a
significant apoptotic response in human NSCLCs [21]. We therefore
treated both MPM cell lines with 0.25 to 2 μM MG132 and then
analyzed MG132’s cytotoxicity. It was observed in cell proliferation
assay that greater than 0.25 μM MG132 caused a clear inhibition of
cell proliferation in a 4-day observation period in both cell lines,
whereas greater than 0.5 μMMG132 induced a significant cell death
with a higher potency demonstrated in NCI-H2452 cells (Figure 1A).
A WST-1 cell viability assay indicated that most cells from both
MPM cell lines died at 72 hours after exposure to greater than
1 μM MG132, with more significant cell death seen again in NCI-
H2452 cells (Figure 1B). To determine the apoptosis induction by
MG132, we tested DNA fragmentation in MPM cells by examining
sub–G0/G1 cells in a flow cytometry assay [18]. A dose-dependent
increase in sub–G0/G1 cells was observed in both cell lines at 36 to
48 hours after exposure to MG132, suggesting an apoptosis induction
in tumor cells (Figure 1C ). In addition to the increase of sub–G0/G1
population, a clear increase in G2/M cells, or G2/M arrest, was also
observed in both cell lines (Figure 1C ).
Caspase Activation Is Involved in MG132-Induced Apoptosis
Previous work demonstrated that various caspases are involved in
PI-induced apoptosis in other types of tumor cells [19]. To analyze
the MG132-induced apoptosis in MPM cells, we examined cleavage
activities of caspases 3, 7, 8, and 9 as well as cleavage of PARP, a
prominent substrate of executioner caspases, in both MPM cell lines
after treatment with MG132. A significant increase in cleavage ac-
tivities of caspases 3, 9, and 8 detected in caspase cleavage assay
was observed in both cell lines in response to greater than 0.5 μM
MG132 (Figure 2A). A dose-dependent cleavage for caspases 3 and
7 and PARP was further demonstrated by Western blot analysis in
both cell lines (Figure 2B). Consistent with other parameters of
apoptotic cell death, NCI-H2452 cells showed a more significant
protein cleavage than NCI-H2052 cells. In addition, Bid protein
cleavage was also observed in MG132-treated NCI-H2452 cells
(Figure 2B-1). To determine whether the MG132-induced apoptosis
is dependent on caspase activation, we cotreated NCI-H2452 cells
with 1 μM MG132 and 10 μM of each caspase specific inhibitor.
Z-FA-fmk was used as a negative control for all caspase inhibitors.
It was observed that treatment with Z-VAD-fmk, Z-IETD-fmk, or
Z-LEHD-fmk significantly reduced MG132-induced cleavage of
PARP and caspase 7 as observed in Western blot analysis (Figure 2C )
and significantly suppressed MG132-induced cell death as seen in
the WST-1 assay (Figure 2D), demonstrating that MG132-induced
apoptosis is caspase-dependent.
Mitochondrial Caspase Activation Pathway Is Responsible for
MG132-Induced Apoptosis
To determine whether the mitochondrial pathway is involved in
MG132-induced apoptosis, we then tested mitochondrial release of
Cyto c and Smac into the cytosol after treatment with MG132 in
both MPM cell lines. A more abundant release of Smac with a less
abundant release of Cyto c was observed in Western blot analysis sup-
porting that the mitochondrial pathway was activated by MG132
(Figure 3A). Subsequently, we examined protein levels of Bcl-2,
Bcl-XL, and Mcl-1, the Bcl-2 antiapoptotic family proteins, in
MG132-treated cells. MG132 treatment caused no changes in Bcl-
2 and Bcl-XL, but induced a significant, dose-dependent elevation of
the 40-kDa-long isoform Mcl-1 protein (or Mcl-1L; Figure 3B). No
short Mcl-1 isoform (30 kDa or Mcl-1S) was observed. Therefore,
these data supported that the mitochondrial apoptotic pathway was
activated by MG132 and the Mcl-1 protein (or Mcl-1L) is likely a
negative regulator of activation of this pathway.
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IAPs are another group of apoptosis regulatory proteins, which
include c-IAP1, XIAP, and Survivin and inhibit apoptosis by binding
to different caspases [22]. In this study, we also examined protein
levels for c-IAP1, XIAP, and Survivin. It was revealed by Western blot
analysis that the c-IAP1 level was slightly reduced by MG132 in
both MPM cell lines, whereas the Survivin level was lowered in
NCI-H2052 cells but elevated in NCI-H2452 cells by MG132.
However, the XIAP protein level was clearly increased in both cell
132 MG132 Possesses Anti-Mesothelioma Activities Yuan et al. Translational Oncology Vol. 1, No. 3, 2008
lines, suggesting that XIAP may serve as another negative regulator for
MG132-induced apoptosis (Figure 3B).
Silencing of Mcl-1 Protein Expression by siRNA Sensitizes
MPM Cells to MG132-Induced Apoptosis
To determine the regulatory effect of Mcl-1 and XIAP on MG132-
induced apoptosis, we used siRNA to silence expression of each pro-
tein in MPM cells before MG132 treatment. The scrambled siRNA
was used as control siRNA. NCI-H2052 cells were chosen in this
experiment because NCI-H2052 cells displayed a lower response
to MG132-induced apoptosis than NCI-H2452 cells, probably
through a more elevated Mcl-1 protein level (Figure 3B). It was ob-
served that only Mcl-1 siRNA enhanced MG132-induced cell death
(Figure 4A), which was accompanied by the increased protein cleav-
age for PARP and caspase 3 (Figure 4, A and B-1) although both
Mcl-1 and XIAP siRNAs significantly reduced expression of each
protein (Figure 4, B-1 and B-2). Although Mcl-1 siRNA alone in-
duced a slightly visible caspase 3 cleavage, the most significant apop-
tosis was only observed after Mcl-1 siRNA transfection and MG132
treatment (Figure 4B-1), suggesting that Mcl-1 is a major regulator
of the MG132-induced apoptosis. Further tests revealed that Mcl-1
siRNA also assisted MG132 in inducing Bid protein cleavage with
a subsequent increase in mitochondrial release of Smac and caspase
9 activation (Figure 4, C and D). These observations strongly suggest
that Mcl-1 acts as a major survival molecule in restricting MG132-
induced apoptosis in MPM cells.
Low-Dose MG132 Inhibits In Vitro MPM Cell Invasion
Because invasion is involved in both mortality and morbidity of
MPM, thoracic MPM in particular [1], we also analyzed whether
MG132 possesses an anti-invasion activity in MPM cells. To dis-
tinguish such possible effect from a proapoptotic effect, MPM cells
were treated with subapoptotic doses of MG132 (<0.25 μM), which
elicited no visible apoptotic response in both MPM cell lines. It
was observed that subapoptotic doses of MG132, from 0.125 to
0.0625 μM, exhibited no effects on the viability or mobility of both
MPM cell lines as revealed by a migration assay and a cell prolif-
eration assay (data not shown). However, they significantly inhib-
ited Matrigel invasion of both MPM cell lines in a dose-dependent
manner (Figure 5), demonstrating that whereas higher concentra-
tions of MG132 induce apoptosis in MPM cells, lower concentra-
tions of MG132 inhibit invasion of MPM cells.
MG132-Inhibited Invasion of MPM Cells Is Independent of
Src Activity
Increased Src activity is generally associated with the enhanced
motility and invasion of cancer cells [23]. To examine the change
of Src activity in MG132-treated MPM cells, we tested Src phos-
phorylation at tyrosine 527 (Tyr527) and 416 (Tyr416) residues,
which represent inactive and active forms of the Src kinase, respec-
tively [24]. Apoptotic doses of MG132 (>0.25 μM) clearly reduced
Src phosphorylation at Tyr416 in both MPM cell lines (Figure 6A).
However, subapoptotic doses of MG132 (<0.25 μM) exhibited no
such effect (data not shown). In addition, MG132 did not induce
a visible change in Src phosphorylation at the Tyr527 residue,
which was much more robust than the phosphorylation at Tyr416
in both cell lines regardless of MG132 treatment (Figure 6A). We
next treated both MPM cell lines with an Src kinase–specific inhib-
itor (type I) to determine whether inhibition of the Src signaling can
reduce MPM cell invasion. NCI-H358, a human NSCLC cell line
that exhibits a high sensitivity to the Src inhibitor, was used as a
positive control in this test. It was observed that 10 μM Src kinase
inhibitor dramatically reduced migration of NCI-H358 cells (Fig-
ure 6B) but did not inhibit invasion of either MPM cell line (Fig-
ure 6B), suggesting that invasion by MPM cells tested in this study
is independent of Src activity.
Inhibition of Rac1 Activation Contributes to
MG132-Inhibited MPM Cell Invasion
Rho subfamily members of the small GTPase Ras superfamily pro-
teins, such as RhoA, Cdc42, and Rac1, represent another category of
proteins that mediate tumor cell metastasis mainly through regulat-
ing actin cytoskeleton reorganization [25]. The activity of these pro-
teins is switched on and off through a GTP- to GDP-binding cycling
[25]. To further analyze MG132-inhibited MPM cell invasion, we
performed a pull-down assay to determine the change of activity of
the RhoA, Cdc42, and Rac1 proteins in response to MG132 treat-
ment in NCI-H2452 cells, which displayed a higher invasion po-
tential than NCI-H2052 cells. The GTP-bound Rac1 protein, but
not the RhoA and Cdc42 proteins, was significantly reduced by sub-
apoptotic doses of MG132 in a dose-dependent manner (Figure 7A),
suggesting that reduction of Rac1 activity may be responsible for
MG132-inhibited MPM cell invasion. To support this observation,
we stably transfected a cDNA of a constitutively active Rac1 mutant,
Rac1-G12V, into NCI-H2452 cells to first determine the effect of
the mutant Rac1 on MPM cell invasion. Expression of Rac1-G12V,
confirmed by Western blot analysis (Figure 7B-1), conferred a more
invasive potential to MPM cells, especially during the earlier time of
cell invasion (Figure 7B-2). It was next observed that the Rac1-G12V
mutant significantly reduced MG132-inhibited NCI-H2452 cell
invasion (Figure 7B-3), further supporting that Rac1 serves as a target
of inhibition of tumor cell invasion by MG132.
Discussion
The lethality of MPM is due to both the resistance to currently
available chemotherapies through its evasion of apoptosis induction
Figure 1.MG132 induces apoptotic cell death in human MPM cells. (A) Cell proliferation assay indicates that greater than 0.5 μMMG132
induces significant cell death in both NCI-H2452 and NCI-H2052 cells. Values are expressed as the means ± SD of two experiments. *P <
.05 versus control. (B) Cell viability assay using WST-1 reagent shows that most cells in both MPM cell lines died at 72 hours after treat-
ment with greater than 1 μM MG132. Values are expressed as the means ± SD of three experiments. *P < .05 versus control. (C) Flow
cytometry assay demonstrates that MG132 induces the appearance of sub–G0/G1 cells with a distinct peak in both MPM cell lines in a
dose-dependent manner. A clear increase in G2/M cells in both cell lines is also indicated. The assay was performed at 36 hours for NCI-
H2452 cells and 48 hours for NCI-H2052 cells after treatment with MG132.
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and invasion, mediastinal invasion in particular for thoracic MPM.
New agents that restore the sensitivity of MPM cells to apoptosis
induction and inhibit MPM cell invasion will be desirable candi-
dates for treating MPM. We demonstrate in the present study that
MG132 possesses the dual abilities of both inducing MPM cell apop-
tosis in a caspase-dependent manner and inhibiting MPM cell in-
vasion through suppressing Rac1 activity. The two MPM cell lines
used in this study derived from two major pathologic subtypes of
MPM: NCI-H2052 was from an epithelial MPM, whereas NCI-
H2452 was from a sarcomatoid MPM, suggesting a wide coverage
of MG132’s effect on major types of MPMs. Therefore, MG132,
and possibly other PIs as well, may represent a new and efficient
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treatment that targets two critical molecular processes associated with
the aggressiveness of MPM.
MG132-induced apoptosis in MPM cells is caspase-dependent. As
revealed in this study, MG132-induced apoptosis is accompanied by
the activation of caspases 3, 7, 8, and 9; inhibition of caspase activa-
tion by the inhibitors either for wide spectrum caspases or specifically
for caspases 8 and 9 resulted in the inhibition of MG132-induced
apoptotic cell death. It is also believed that caspase-dependent apop-
tosis is mediated by the mitochondria, which are activated by the
truncated Bid protein and then release both Smac and Cyto c into
the cytosol, leading to sequential activation of caspase 9 and caspase
3/7, and eventually to apoptotic cell death.
It was noted that the Smac protein released from the mitochondria
was more abundant than the Cyto c protein. This notion is in agree-
ment with the findings in other types of cancer cells treated with PIs
[19,20]. A recent observation in our laboratory also showed that mi-
tochondrial release of the Smac protein happens much earlier than
that of the Cyto c protein during MG132-induced apoptosis of lung
cancer cells, supporting the view that the Smac protein is more crit-
ical than the Cyto c protein in initiating PI-induced apoptosis [21].
The dominance of Smac over Cyto c may be attributable to MG132-
induced stabilization of the Smac protein. The Smac protein released
from the mitochondria on apoptotic stimuli can be rapidly bound by
XIAP and directed toward proteasomal degradation. In addition to its
well-characterized antiapoptotic function in binding and inhibiting
caspases, XIAP, c-IAP1, and c-IAP2 also target proapoptotic mole-
cules for proteasomal degradation to protect cells from inadvertent
mitochondrial damage [19,26]. Indeed, a RING finger domain in
the XIAP protein possessing ubiquitin protein ligase activity was
found to be essential for ubiquitination and degradation of the Smac
Figure 2.MG132 induces a caspase-dependent apoptosis in both MPM cell lines. All assays were performed at 36 hours for NCI-H2452
cells and 48 hours for NCI-H2052 cells after treatment with MG132. (A) Caspase activation assay demonstrates that MG132 activates
caspases 3, 9, and 8 in a dose-dependent manner. Values are expressed as the means ± SD of three experiments. *P < .05 versus
control. (B) Western blot analysis shows that MG132 treatment induces cleavage of caspases 3 and 7, Bid, and PARP in NCI-H2452 cells
(B-1) and induces cleavage of the caspases 3 and 7 and PARP proteins in NCI-H2052 cells (B-2). Protein cleavage fragments are indicated
by arrows. (C and D) Inhibitors, 10 μM, for broad spectrum caspases (Z-VAD-fmk), caspase 8 (Z-IETD-fmk), or for caspase 9 (Z-LEHD-fmk)
inhibit MG132-induced cleavages for caspase 7 and PARP (C) as revealed by Western blot analysis and inhibit MG132-induced cell death
as demonstrated by cell viability assay using WST-1 reagent (D). Protein cleavage fragments in Western blot analysis are indicated by
arrows. Values from WST-1 assay are expressed as the means ± SD of three experiments. *P < .05 for caspase inhibitors plus MG132
versus Z-FA-fmk plus MG132.
Figure 3. MG132 induces mitochondrial release of proapoptotic proteins and elevates the Mcl-1 protein in both MPM cell lines. All anal-
yses were performed at 36 hours for NCI-H2452 cells and 48 hours for NCI-H2052 cells after treatment with MG132. (A) Western blot
analysis indicates thatMG132 inducesmitochondrial release of the Smac andCyto c proteins into the cytosol in a dose-dependentmanner.
Cell lysates were isolated and analyzed from the cytosol portion of each sample. (B)Western blot analysis demonstrates that, among Bcl-2
and IAP family proteins tested, the dose-dependent elevation of Mcl-1 represents the most significant change induced by MG132.
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protein [26]. Therefore, given that MG132 is a strong proteasome
inhibitor, the caspase activation observed in MG132-treated MPM
cells is likely achieved at least in part through Smac stabilization.
Among the antiapoptotic proteins of both IAP and Bcl-2 families
tested, Mcl-1 (or Mcl-1L) proved to be the major survival molecule to
regulate MG132-induced apoptosis in MPM cells. Both Mcl-1 of the
antiapoptotic Bcl-2 family proteins and XIAP of the IAP family pro-
teins displayed protein elevation in two MPM cell lines in response
to MG132 treatment. However, Mcl-1 demonstrated a much more
consistent and higher protein elevation than XIAP. Moreover, it is
Mcl-1 siRNA, but not XIAP siRNA, that significantly enhanced
MG132-induced apoptosis in MPM cells. The concomitant elevation
of the Mcl-1 protein in MPM cells is believed to be the consequence
of MG132-induced proteasome inhibition as the Mcl-1 protein
is also subjected to proteasome-mediated degradation [27,28]. Mul-
tiple mechanisms have been proposed for the protection by Mcl-1
Figure 4.Mcl-1 siRNA sensitizes NCI-H2052 cells to MG132-induced apoptosis. All analyses were performed at 48 hours after treatment
with MG132. Cell viability assay using WST-1 reagent shows that Mcl-1 siRNA, but not XIAP siRNA, significantly sensitizes MPM cells to
MG132-induced cell death (A). Values are expressed as means ± SD of two experiments. *P < .05 for siMcl-1 versus siControl. Western
blot analysis indicates that both Mcl-1 and XIAP siRNAs reduce the expression of each protein (B-1 and B-2). However, it is Mcl-1 siRNA
(B-1), but not XIAP siRNA (B-2), that increases MG132-induced cleavage for PARP and caspase 3 (B-1). Mcl-1 siRNA also enhances Bid
and caspase 9 protein cleavages with increased mitochondrial release of the Smac protein (C and D). Protein cleavage fragments in
Western blot analysis are indicated by arrows.
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Figure 5. Subapoptotic doses of MG132 inhibits MPM cell invasion. A total of 1 × 105 cells were seeded in each Matrigel-coated trans-
well and incubated for 48 hours with different concentrations of MG132. Invasive cells at the lower side of each transwell membrane
were fixed and stained by Diff-Quick solutions and quantified. The quantitative values expressed as the means ± SD of five microscopic
fields are representative of two separate experiments. *P < .05 versus control.
Figure 6. MPM cell invasion is independent of Src protein activity. (A) Western blot analysis reveals that apoptotic doses of MG132
reduce phosphorylation of Src at Tyr 416 residue in both MPM cell lines. (B) Migration or invasion assays demonstrate that 10 μM Src
inhibitor I, which dramatically reduces migration of NCI-H358 cells, exhibits no effect on invasion of both MPM cell lines. A total of 2 ×
105 NCI-H358 cells were used in the migration assay, and the migratory cells were stained at 24 hours after treatment with Src inhibitor I.
A total of 1 × 105 cells of each MPM cell line were used in a Matrigel invasion assay, and the invasive cells were stained at 36 hours after
treatment with Src inhibitor I.
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from apoptotic damage. For example, Mcl-1 inhibits death receptor–
mediated apoptosis by interacting with the truncated Bid protein
causing inhibition of Cyto c release from the mitochondria, indicat-
ing that Mcl-1 acts as an antiapoptotic molecule in parallel or down-
stream of Bid protein activation [29]. However, the finding that Mcl-1
siRNA enhances MG132-induced Bid protein cleavage suggests that
Mcl-1’s action in MPM cells is, in contrast, upstream of Bid protein
activation probably through a positive feedback mechanism [21].
Therefore, while MG132 activates multiple caspases to drive apopto-
tic cell death, it also elevatesMcl-1, most likely through inhibiting pro-
teasomes, which then restrains such apoptotic response.
Inhibition of MPM cell invasion by MG132 represents a newly
discovered anticancer activity of PIs. Such activity is independent
of its proapoptotic activity because it can be achieved by subapopto-
tic doses of MG132. Several signaling pathways, such as c-Met/HGF
and Src signaling, have been reported to mediate different aspects of
Figure 7. Rac1 activity is associated with MPM cell invasion and serves as a target for MG132 in its inhibition of MPM cell invasion. (A)
Western blot analysis after pull-down assays shows that, among Rac1, Cdc42, and RhoA, the GTP-bound Rac1 protein was most sig-
nificantly reduced by subapoptotic doses of MG132 in a dose-dependent manner. (B) Expression of the Rac1-G12V protein, confirmed
by Western blot analysis using an anti–HA antibody (B-1), promotes invasion of NCI-H2452 cells as assayed at 24 hours (B-2) and re-
duces the induction of MG132-inhibited MPM cell invasion (B-3). Values expressed as the mean ± SD of five microscopic fields are
representative of two separate experiments. *P < .05 for Rac1-G12V versus vector alone.
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MPM’s tumorigenicity [30–32]. However, based on our analyses,
both Src and c-Met/HGF are less likely to be directly involved in
invasion of both MPM cell lines tested in this study. Both MPM
cell lines are not responsive to a c-Met inhibitor in terms of cell
proliferation and migration, although NCI-H2452 cell line expresses
a high level of the c-Met protein [30,31]. Although apoptotic doses
of MG132 can reduce Src activation as evidenced by the reduced
phosphorylation of Src at Tyr416 in Western blot analysis, the
subapoptotic dosages of MG132 that can inhibit MPM cell inva-
sion exhibited no effect on Src activation. In addition, an Src-specific
inhibitor, which inhibits migration of a human NSCLC cell line,
showed no effect on both migration and invasion of MPM cells.
The insensitivity of both MPM cell lines to the inhibition by both
c-met and Src inhibitors suggests that other signaling molecules
other than c-Met/HGF and Src are more involved in mediating
MPM cell invasion and may be a target of MG132 in inhibiting
MPM cell invasion.
Rac1 is believed to be a target of MG132 in its inhibition of MPM
cell invasion. Increased Rac1 activity has been tightly associated with
enhanced cell motility and invasion [25]. However, its involvement
in MPM cell invasion has not been addressed. Among the small
GTPase Rho subfamily proteins tested in this study, only Rac1
showed a significant reduction in GTP-bound form in response to
MG132 treatment as seen in a pull-down assay. Also, the Rac1 pro-
tein level seems to be higher than both RhoA and Cdc42 in MPM
cells. Most importantly, transfection of a constitutively active Rac1
mutant can further promote MPM cell invasion and partially block
MG132-induced inhibition of MPM cell invasion. These findings
support that the Rac1 protein is involved in MPM cell invasion
and serves as a target of MG132 although it is not the only target.
Rac1 activity is regulated by Tiam1, Rac1’s specific guanine nucleo-
tide exchange factor, which activates Rac1 and promotes tumor cell
invasion by converting GDP-bound Rac1 into GTP-bound Rac1
[33], and by Rac1 specific Rho GTP activating protein (RhoGAP),
yet to be identified, which inactivates Rac1 by catalyzing GTP-
bound Rac1 into GDP-bound Rac1. Activated Rac1 is reported to
be degraded by proteasomes in certain types of cells undergoing spe-
cial treatment [34]. However, the reduction of Rac1 activity in
MG132-treated MPM cells is unlikely to be the primary conse-
quence of proteasome inhibition, rather it may be achieved through
activation of Rac1’s RhoGAP or inactivation of Tiam1 by yet un-
known mechanisms.
In summary, the present study demonstrates that proteasome in-
hibitor MG132 may represent a promising new treatment of MPM,
which induces apoptosis as well as inhibits invasion of MPM cells.
Because the concomitant increase of Mcl-1 protein inhibits MG132-
induced apoptosis, other treatments for down-regulating Mcl-1 expres-
sion are needed to synergize with MG132 in treating MPM. Mcl-1
siRNA, Mcl-1 small molecule inhibitor, or inhibitors of other signal-
ing molecules, such as the inhibitor of STAT3, are potentially effi-
cient cotreatments with MG132. Indeed, Mcl-1 siRNA has proved
to be effective in enhancing MG132-induced apoptosis in this study.
STAT3 acts as a survival protein by up-regulating Mcl-1, c-Myc,
Cyclin D1, and Bcl-XL at the transcriptional level in tumor cells
[35]. Further investigation of the synergy between PIs and differ-
ent inhibitors of signaling pathways will provide new insights into de-
veloping more efficient PI-based combination therapies for MPM
treatment. In addition, further investigation of Rac1 in MPM cell in-
vasion may help develop new diagnostic markers to measure the
invasion potential of MPM cells and to guide the usage of PIs in
treating MPM.
Acknowledgments
The authors thank Robert Lanciotti (National Institute for Occu-
pational Safety and Health) for his assistance with the flow cytome-
try assay.
Disclaimer
The findings and conclusions in this report are those of the authors
and do not necessarily represent the views of the Centers for Dis-
ease Control and Prevention, the National Institute for Occupa-
tional Safety and Health of the Agency for Toxic Substances and
Disease Registry.
References
[1] Antman KH (1981). Clinical presentation and natural history of benign and
malignant mesothelioma. Semin Oncol 8 (3), 313–320.
[2] Price B (1997). Analysis of current trends in United States mesothelioma inci-
dence. Am J Epidemiol 145 (3), 211–218.
[3] Zucali PA and Giaccone G (2006). Biology and management of malignant pleu-
ral mesothelioma. Eur J Cancer 42 (16), 2706–2714.
[4] Goudar RK (2005). New therapeutic options for mesothelioma. Curr Oncol Rep
7 (4), 260–265.
[5] Krug LM (2005). An overview of chemotherapy for mesothelioma. Hematol
Oncol Clin North Am 19 (6), 1117–1136, vii.
[6] Govindan R, Kratzke RA, Herndon JE, Niehans GA, Vollmer R, Watson D,
Green MR, and Kinkler HL (2005). Gefitinib in patients with malignant me-
sothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer
Res 11 (6), 2300–2304.
[7] Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P,
Gatzemeier U, Boyer M, Emri S, Manegold C, et al. (2003). Phase III study
of pemetrexed in combination with cisplatin versus cisplatin alone in patients
with malignant pleural mesothelioma. J Clin Oncol 21 (14), 2636–2644.
[8] Cryns V and Yuan J (1998). Proteases to die for. Genes Dev 12 (11), 1551–1570.
[9] Jiang X and Wang X (2004). Cytochrome C–mediated apoptosis. Annu Rev
Biochem 73, 87–106.
[10] Cory S, Huang DC, and Adams JM (2003). The Bcl-2 family: roles in cell sur-
vival and oncogenesis. Oncogene 22 (53), 8590–8607.
[11] Kozopas KM, Yang T, Buchan HL, Zhou P, and Craig RW (1993). MCL1, a
gene expressed in programmed myeloid cell differentiation, has sequence simi-
larity to BCL2. Proc Natl Acad Sci USA 90 (8), 3516–3520.
[12] Michels J, Johnson PW, and Packham G (2005). Mcl-1. Int J Biochem Cell Biol
37 (2), 267–271.
[13] Bingle CD, Craig RW, Swales BM, Singleton W, Zhou P, and Whyte MK
(2000). Exon skipping in Mcl-1 results in a bcl-2 homology domain 3 only gene
product that promotes cell death. J Biol Chem 275 (29), 22136–22146.
[14] Craig RW (2002). MCL1 provides a window on the role of the BCL2 family in
cell proliferation, differentiation and tumorigenesis. Leukemia 16 (4), 444–454.
[15] Adams J (2004). The development of proteasome inhibitors as anticancer drugs.
Cancer Cell 5 (5), 417–421.
[16] Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL,
Salgia R, Sugrabaker DJ, and Bueno R (2008). Preclinical studies of the protea-
some inhibitor bortezomib in malignant pleural mesothelioma.Cancer Chemother
Pharmacol 61 (4), 549–558.
[17] Sun X, Gulyas M, Hjerpe A, and Dobra K (2006). Proteasome inhibitor PSI
induces apoptosis in human mesothelioma cells. Cancer Lett 232 (2), 161–169.
[18] Das T, Sa G, Sinha P, and Ray PK (1999). Induction of cell proliferation and
apoptosis: dependence on the dose of the inducer. Biochem Biophys Res Commun
260 (1), 105–110.
[19] Henderson CJ, Aleo E, Fontanini A, Maestro R, Paroni G, and Brancolini C
(2005). Caspase activation and apoptosis in response to proteasome inhibitors.
Cell Death Differ 12 (9), 1240–1254.
[20] Nagy K, Szekely-Szuts K, Izeradjene K, Douglas L, Tillman M, Barti-Juhasz H,
Dominici M, Spano C, Luca CG, Conte P, et al. (2006). Proteasome inhibitors
sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release
of Smac/DIABLO from the mitochondria. Pathol Oncol Res 12 (3), 133–142.
Translational Oncology Vol. 1, No. 3, 2008 MG132 Possesses Anti-Mesothelioma Activities Yuan et al. 139
[21] Yuan B, Chapman J, and Reynolds SH (2008). Culmination of MG132-induced
apoptosis depends on a positive feedback of caspase activation andMcl-1 cleavage.
AACR Annual Meeting Proceedings. Santiago, CA. [Abstract 3352]. p. 796.
[22] Hunter AM, LaCasse EC, and Korneluk RG (2007). The inhibitors of apoptosis
(IAPs) as cancer targets. Apoptosis 12 (9), 1543–1568.
[23] Hauck CR, Hsia DA, and Schlaepfer DD (2002). The focal adhesion kinase—a
regulator of cell migration and invasion. IUBMB Life 53 (2), 115–119.
[24] Hunter T (1987). A tail of two src’s: mutatis mutandis. Cell 49 (1), 1–4.
[25] Frame MC and Brunton VG (2002). Advances in Rho-dependent actin regula-
tion and oncogenic transformation. Curr Opin Genet Dev 12 (1), 36–43.
[26] MacFarlane M, Merrison W, Bratton SB, and Cohen GM (2002). Proteasome-
mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiqui-
tination in vitro. J Biol Chem 277 (39), 36611–36616.
[27] Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, and Wang X (2003).
Elimination of Mcl-1 is required for the initiation of apoptosis following ultra-
violet irradiation. Genes Dev 17 (12), 1475–1486.
[28] Zhong Q, Gao W, Du F, and Wang X (2005). Mule/ARF-BP1, a BH3-only E3
ubiquitin ligase, catalyzes the polyubiquitination ofMcl-1 and regulates apoptosis.
Cell 121 (7), 1085–1095.
[29] Clohessy JG, Zhuang J, de Boer J, Gil-Gomez G, and Brady HJ (2006). Mcl-1
interacts with truncated Bid and inhibits its induction of cytochrome c release
and its role in receptor-mediated apoptosis. J Biol Chem 281 (9), 5750–5759.
[30] Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V,
Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, et al. (2006). Functional analysis
of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
Cancer Res 66 (1), 352–361.
[31] Mukohara T, Civiello G, Davis IJ, TaffaroML, Christensen J, Fisher DE, Johnson
BE, and Janne PA (2005). Inhibition of the met receptor in mesothelioma. Clin
Cancer Res 11 (22), 8122–8130.
[32] Tsao AS, He D, Saigal B, Lui S, Lee JJ, Bakkannagari S, Ordonez NG, Hong
WK, Wistuba I, and Johnson FM (2007). Inhibition of c-Src expression and
activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle
arrest, and decreased migration and invasion. Mol Cancer Ther 6 (7), 1962–
1972.
[33] Stam JC, Michiels F, van der Kammen RA, Moolenaar WH, and Collard JG
(1998). Invasion of T-lymphoma cells: cooperation between Rho family GTPases
and lysophospholipid receptor signaling. EMBO J 17 (14), 4066–4074.
[34] Munro P, Flatau G, Doye A, Boyer L, Oregioni O, Mege JL, Landraud L, and
Lemichez E (2004). Activation and proteasomal degradation of rho GTPases by
cytotoxic necrotizing factor-1 elicit a controlled inflammatory response. J Biol
Chem 279 (34), 35849–35857.
[35] Buettner R, Mora LB, and Jove R (2002). Activated STAT signaling in human
tumors provides novel molecular targets for therapeutic intervention. Clin Cancer
Res 8 (4), 945–954.
140 MG132 Possesses Anti-Mesothelioma Activities Yuan et al. Translational Oncology Vol. 1, No. 3, 2008
